Pre-Covid life could return as early as April 2022, University of East Anglia professor of medicine Paul Hunter made such an encouraging statement.
According to him, COVID-19 is weakening, and by spring it may turn into just “another cause of a cold.” Hunter is confident that covid-positive people should be allowed to live their normal lives.
By the way, Japanese scientists are now developing a vaccine that provides lifelong immunity and can be transported at room temperature, based on another vaccine against smallpox.
APnews writes that the shot will be given “once and for all,” like some childhood shots, and its effects will last a lifetime. According to one of the creators of the vaccine, scientist Michinori Kohara from the Tokyo Institute of Medical Sciences, the development of a new drug was based on an anti-small vaccine created by British doctor Edward Jenner back in 1796.
According to The Japan Times, in April 2020, the Tokyo Institute, together with the National Institute of Infectious Diseases, began the development of “a recombinant vaccinia virus containing the spike protein of the SARS-CoV-2 virus that causes COVID-19.”
The creators chose a non-pathogenic strain of a variant of the vaccinia virus called DIs, “which works as an extremely efficient and safe viral vector to deliver the SARS-CoV-2 spike gene.”
The drug they ended up with showed miraculous results: the number of neutralizing antibodies in mice did not decrease even 20 months after the injection. And in a study on macaques, a positive “side effect” was that the vaccine formed protection against pneumonia in primates.
Japanese pharmaceutical company Nobelpharma has scheduled Phase 1 and Phase 2 clinical trials for the vaccine in 2023, with 150 to 200 volunteers, both those vaccinated with the available COVID-19 vaccines and those who have been ill, Kohara said.
“If clinical trials are successful, then their third phase will immediately begin, the goal of entering the markets is at the earliest in 2024,” the scientist said.